

04/01

Docket No. A061CIP2

#5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Gregory R. Mundy and Toshiyuki Yoneda
Application No.: 10/086,217
Confirmation No.: 5114
Filed : February 21, 2002
For : METHODS OF TREATING MULTIPLE MYELOMA AND
MYELOMA-INDUCED BONE RESORPTION USING
INTEGRIN ANTAGONISTS
Group Art Unit : 1644
Examiner : Not yet assigned

New York, New York
June 21, 2002

Hon. Commissioner
for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER FOR
INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith is an Information Disclosure
Statement in the above-identified application. This
Statement is submitted:


- ☐ [] within three months of the application filing date;
- ☒ [X] more than three months from the application filing date but before the mailing date of the first Office Action on the merits.

In accordance with 37 C.F.R. § 1.97, submission of
this Statement requires no fee. However, if for any reason
a fee is due, the Director is hereby authorized to charge

EI187452145US

payment of any fees required in connection with this
Information Disclosure Statement to Deposit Account
No. 06-1075. A duplicate copy of this letter is transmitted
herewith.

Respectfully submitted,



James F. Haley, Jr. (Reg. No. 27,794)
Attorney for Applicants
Stanley D. Liang (Reg. No. 43,753)
Agent for Applicants
c/o FISH & NEAVE
Customer No. 1473
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (212) 596-9000



A061CIP2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Gregory R. Mundy and Toshiyuki Yoneda
Application No. : 10/086,217
Confirmation No. : 5114
Examiner : Not yet assigned
Group Art Unit : 1644
Filed : February 21, 2002
For : METHODS OF TREATING MULTIPLE MYELOMA AND
MYELOMA-INDUCED BONE RESORPTION USING
INTEGRIN ANTAGONISTS

New York, New York
June 21, 2002

Hon. Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97 AND 1.56

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants make of record the following
document in the above-identified patent application, copies of which are submitted herewith:

United States Patent Application Publications

Mundy et al.	US 2002/0022028 A1	published February 21, 2002
Mundy et al.	US 2002/0041874 A1	published April 11, 2002

EI187452145US

Other References

Alsina, M. et al., "Development of an In Vivo Model of Human Multiple Myeloma Bone Disease," BLOOD 87: 1495-1501 (1996).

Attal, M. et al., "A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma," N ENGL J MED 335: 91-97 (1996).

Atkins, C., "Correspondence: High-Dose Chemotherapy in Multiple Myeloma," N ENGL J MED 335: 1844 (1996).

Oivanen, T. M. et al., "Correspondence: High-Dose Chemotherapy in Multiple Myeloma," N ENGL J MED 335: 1844-1845 (1996).

Attal, M. et al., "Correspondence: High-Dose Chemotherapy in Multiple Myeloma - In Reply," N ENGL J MED 335: 1844-1845 (1996).

Barlogie, B. et al., "Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients," BLOOD 98: 492-494 (2001).

Bataille, R. et al., "Serum Levels of Interleukin 6, a Potent Myeloma Cell Growth Factor, as a Reflect of Disease Severity in Plasma Cell Dyscrasias," J CLIN INVEST 84: 2008-2011 (1989).

Bataille, R. et al., "Mechanisms of Bone Lesions In Multiple Myeloma," HEMATOLOGY/ONCOLOGY CLINICS OF NORTH AMERICA 6: 285-295 (1992).

Bataille, R. et al., "Biologic Effects of Anti-Interleukin-6 Murine Monoclonal Antibody in Advanced Multiple Myeloma," BLOOD 86: 685-691 (1995).

Berenson, J. R. et al., "Long-Term Pamidronate Treatment of Advanced Multiple Myeloma Patients Reduces Skeletal Events," J CLIN ONCOL 16: 593-602 (1998).

Seymour, J. F., "Correspondence: Long-Term Pamidronate in Multiple Myeloma," J CLIN ONCOL 16: 2572 (1998).

Berenson, J. R., "Correspondence: Long-Term Pamidronate in Multiple Myeloma - In Reply," J CLIN ONCOL 16: 2572-2573 (1998).

Boyce, B. F. et al., "Bolus Injections of Recombinant Human Interleukin-1 Cause Transient Hypocalcemia in Normal Mice," ENDOCRINOLOGY 125: 2780-2783 (1989).

Chauhan, D. et al., "Regulation of Interleukin 6 in Multiple Myeloma and Bone Marrow Stromal Cells," STEM CELLS 13 (suppl 2): 35-39 (1995).

Dallas, S. L. et al., "Ibandronate Reduces Osteolytic Lesions but not Tumor Burden in a Murine Model of Myeloma Bone Disease," BLOOD 93: 1697-1706 (1999).

Epstein, J., "Myeloma Phenotype: Clues To Disease Origin and Manifestation," HEMATOLOGY/ONCOLOGY CLINICS OF NORTH AMERICA 6:249-256 (1992).

Garrett, I. R. et al., "A Murine Model of Human Myeloma Bone Disease," BONE 20: 515-520 (1997).

Gossler, U. et al., "Predominant Role of $\alpha 4$ -integrins for distinct steps of lymphoma metastasis," Proc. Natl. Acad. Sci. USA 93: 4821-4826 (1996).

MacDonald, B. R. et al., "Effects of Human Recombinant CSF-GM and Highly Purified CSF-1 on the Formation of Multinucleated Cells with Osteoclast Characteristics in Long-Term Bone Marrow Cultures," J BONE AND MINERAL RESEARCH 1: 227-233 (1986).

Matsuura, N. et al., "Induction of Experimental Bone Metastasis in Mice by Transfection of Integrin $\alpha 4 \beta 1$ into Tumor Cells," AM J PATHOL 148: 55-61 (1996).

Michigami, T. et al., "Interactions of Myeloma Cells with Bone Marrow Stromal Cells Via $\alpha 4 \beta 1$ Integrin-VCAM-1 Is Required For the Development of Osteolysis," Nineteenth Annual Meeting of the American Society for Bone and Mineral Research, Cincinnati, Ohio: Abstract 104 (9/14/1997); J. BONE AND MINERAL RESEARCH 12 Supplement: p. S218 (1997).

Michigami, T. et al., "Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and $\alpha 4 \beta 1$ -integrin enhances production of osteoclast-stimulating activity," BLOOD 96: 1953-1960 (2000).

Mittelman, M. et al., "Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models," Proc. Natl. Acad. Sci. USA 98: 5181-5186 (2001).

Mori, Y. et al., "Anti- $\alpha 4$ Integrin Antibody Suppresses the Bone Disease of Myeloma and Disrupts Myeloma-Marrow Stromal Cell Interactions," Twenty-First Annual Meeting of the American Society for Bone and Mineral Research, St. Louis, Missouri: Abstract 1161 (10/3/1999); J. BONE AND MINERAL RESERACH 14 Supplement 1: p. S148 (1999).

Mundy, G. R. and Bertolini, D. R., "Bone Destruction and Hypercalcemia in Plasma Cell Myeloma," SEMINARS IN ONCOLOGY 13: 291-299 (1986).

Mundy, G. R., "Myeloma Bone Disease," EURO J CANCER 34: 246-251 (1998).

Oyajobi, B. O. et al., "Expression of Rank Ligand (RankL) By Myeloma Cells Requires Binding To Bone Marrow Stromal Cells Via An $\alpha 4 \beta 1$ -VCAM-1 Interaction," Second

Joint Meeting of The American Society for Bone and Mineral Research and The International Bone and Mineral Society, San Francisco, California: Abstract 1133 (12/4/1998); BONE 23(5 Supplement): p. S180 (1998).

Papayannopoulou, T. and Nakamoto, B., "Peripheralization of hemopoietic progenitors in primates treated with anti-VLA₄ integrin," Proc. Natl. Acad. Sci. USA 90: 9374-9378 (1993).

Qian, F. et al., "Expression of the Integrin $\alpha 4 \beta 1$ on Melanoma Cells Can Inhibit the Invasive Stage of Metastasis Formation," CELL 77: 335-347 (1994).

Shimizu, N. et al., "Disruption of Cell-Cell Contact with Stromal Cells Using Anti- $\alpha 4$ integrin Antibody Enhances Sensitivity of Myeloma Cells to Melphalan in Vitro and in Vivo," Twenty-Third Annual Meeting of the American Society for Bone and Mineral Research, Phoenix, Arizona: Presentation Number SU078 (10/14/2001).

Tinhofer, I. et al., "Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma," BLOOD 95: 610-618 (2000).

Vanderkerken, K. et al., "Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse," BRIT J CANCER 76: 451-460 (1997).

Applicants request that these documents be (1) fully considered by the Examiner during the examination of this application; and (2) printed on any patent that may issue from this application.

Applicants also request that a copy of Form PTO-1449, as considered and initialed by the Examiner, be returned with the next communication.



James F. Haley, Jr. (Reg. No. 27,794)

Attorney for Applicants

Stanley D. Liang (Reg. No. 43,753)

Agent for Applicants

c/o FISH & NEAVE (Customer No. 1473)

1251 Avenue of the Americas

New York, New York 10020-1104

Tel.: (212) 596-9000

Fax.: (212) 596-9090

DEPT. OF COMMERCE
PATENT & TRADEMARK OFFICE

RECEIVED
JUN 21 2002

DEPT. OF COMMERCE
PATENT & TRADEMARK OFFICE

EI187452145US

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANTATTY. DOCKET NO.
A061CIP2SERIAL NO.
10/086,217APPLICANT
Gregory R. Mundy and
Toshiyuki YonedaCONFIRMATION NO.
5114FILING DATE
February 21, 2002GROUP
1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Alsina, M. et al., "Development of an In Vivo Model of Human Multiple Myeloma Bone Disease," <u>BLOOD</u> 87: 1495-1501 (1996).
	Attal, M. et al., "A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma," <u>N ENGL J MED</u> 335: 91-97 (1996).
	Atkins, C., "Correspondence: High-Dose Chemotherapy in Multiple Myeloma," <u>N ENGL J MED</u> 335: 1844 (1996).
	Oivanen, T. M. et al., "Correspondence: High-Dose Chemotherapy in Multiple Myeloma," <u>N ENGL J MED</u> 335: 1844-1845 (1996).
	Attal, M. et al., "Correspondence: High-Dose Chemotherapy in Multiple Myeloma - In Reply," <u>N ENGL J MED</u> 335: 1844-1845 (1996).
	Barlogie, B. et al., "Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients," <u>BLOOD</u> 98: 492-494 (2001).
	Bataille, R. et al., "Serum Levels of Interleukin 6, a Potent Myeloma Cell Growth Factor, as a Reflect of Disease Severity in Plasma Cell Dyscrasias," <u>J CLIN INVEST</u> 84: 2008-2011 (1989).
	Bataille, R. et al., "Mechanisms of Bone Lesions In Multiple Myeloma," <u>HEMATOLOGY/ONCOLOGY CLINICS OF NORTH AMERICA</u> 6: 285-295 (1992).
	Bataille, R. et al., "Biologic Effects of Anti-Interleukin-6 Murine Monoclonal Antibody in Advanced Multiple Myeloma," <u>BLOOD</u> 86: 685-691 (1995).
	Berenson, J. R. et al., "Long-Term Pamidronate Treatment of Advanced Multiple Myeloma Patients Reduces Skeletal Events," <u>J CLIN ONCOL</u> 16: 593-602 (1998).
	Seymour, J. F., "Correspondence: Long-Term Pamidronate in Multiple Myeloma," <u>J CLIN ONCOL</u> 16: 2572 (1998).
	Berenson, J. R., "Correspondence: Long-Term Pamidronate in Multiple Myeloma - In Reply," <u>J CLIN ONCOL</u> 16: 2572-2573 (1998).
	Boyce, B. F. et al., "Bolus Injections of Recombinant Human Interleukin-1 Cause Transient Hypocalcemia in Normal Mice," <u>ENDOCRINOLOGY</u> 125: 2780-2783 (1989).
	Chauhan, D. et al., "Regulation of Interleukin 6 in Multiple Myeloma and Bone Marrow Stromal Cells," <u>STEM CELLS</u> 13 (suppl 2): 35-39 (1995).
	Dallas, S. L. et al., "Ibandronate Reduces Osteolytic Lesions but not Tumor Burden in a Murine Model of Myeloma Bone Disease," <u>BLOOD</u> 93: 1697-1706 (1999).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANTATTY. DOCKET NO.
A061CIP2SERIAL NO.
10/086,217APPLICANT
Gregory R. Mundy and
Toshiyuki YonedaCONFIRMATION NO.
5114FILING DATE
February 21, 2002GROUP
1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


EXAMINER INITIAL	
	Epstein, J., "Myeloma Phenotype: Clues To Disease Origin and Manifestation," <u>HEMATOLOGY/ONCOLOGY CLINICS OF NORTH AMERICA</u> 6:249-256 (1992).
	Garrett, I. R. et al., "A Murine Model of Human Myeloma Bone Disease," <u>BONE</u> 20: 515-520 (1997).
	Gossler, U. et al., "Predominant Role of $\alpha 4$ -integrins for distinct steps of lymphoma metastasis," <u>Proc. Natl. Acad. Sci. USA</u> 93: 4821-4826 (1996).
	MacDonald, B. R. et al., "Effects of Human Recombinant CSF-GM and Highly Purified CSF-1 on the Formation of Multinucleated Cells with Osteoclast Characteristics in Long-Term Bone Marrow Cultures," <u>J BONE AND MINERAL RESEARCH</u> 1: 227-233 (1986).
	Matsuura, N. et al., "Induction of Experimental Bone Metastasis in Mice by Transfection of Integrin $\alpha 4 \beta 1$ into Tumor Cells," <u>AM J PATHOL</u> 148: 55-61 (1996).
	Michigami, T. et al., "Interactions of Myeloma Cells with Bone Marrow Stromal Cells Via $\alpha 4 \beta 1$ Integrin-VCAM-1 Is Required For the Development of Osteolysis," <u>Nineteenth Annual Meeting of the American Society for Bone and Mineral Research, Cincinnati, Ohio: Abstract 104 (9/14/1997); J. BONE AND MINERAL RESEARCH</u> 12 Supplement: p. S218 (1997).
	Michigami, T. et al., "Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and $\alpha 4 \beta 1$ -integrin enhances production of osteoclast-stimulating activity," <u>BLOOD</u> 96: 1953-1960 (2000).
	Mittelman, M. et al., "Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models," <u>Proc. Natl. Acad. Sci. USA</u> 98: 5181-5186 (2001).
	Mori, Y. et al., "Anti- $\alpha 4$ Integrin Antibody Suppresses the Bone Disease of Myeloma and Disrupts Myeloma-Marrow Stromal Cell Interactions," <u>Twenty-First Annual Meeting of the American Society for Bone and Mineral Research, St. Louis, Missouri: Abstract 1161 (10/3/1999); J. BONE AND MINERAL RESEARCH</u> 14 Supplement 1: p. S148 (1999).
	Mundy, G. R. and Bertolini, D. R., "Bone Destruction and Hypercalcemia in Plasma Cell Myeloma," <u>SEMINARS IN ONCOLOGY</u> 13: 291-299 (1986).
	Mundy, G. R., "Myeloma Bone Disease," <u>EURO J CANCER</u> 34: 246-251 (1998).
	Oyajobi, B. O. et al., "Expression of Rank Ligand (RankL) By Myeloma Cells Requires Binding To Bone Marrow Stromal Cells Via An $\alpha 4 \beta 1$ -VCAM-1 Interaction," <u>Second Joint Meeting of The American Society for Bone and Mineral Research and The International Bone and Mineral Society, San Francisco, California: Abstract 1133 (12/4/1998); BONE</u> 23(5 Supplement): p. S180 (1998).
	Papayannopoulou, T. and Nakamoto, B., "Peripheralization of hemopoietic progenitors in primates treated with anti-VLA ₄ integrin," <u>Proc. Natl. Acad. Sci. USA</u> 90: 9374-9378 (1993).
	Qian, F. et al., "Expression of the Integrin $\alpha 4 \beta 1$ on Melanoma Cells Can Inhibit the Invasive Stage of Metastasis Formation," <u>CELL</u> 77: 335-347 (1994).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANTATTY. DOCKET NO.
A061CIP2SERIAL NO.
10/086,217APPLICANT
Gregory R. Mundy and
Toshiyuki YonedaCONFIRMATION NO.
5114FILING DATE
February 21, 2002GROUP
1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Shimizu, N. et al., "Disruption of Cell-Cell Contact with Stromal Cells Using Anti- α 4integrin Antibody Enhances Sensitivity of Myeloma Cells to Melphalan in Vitro and in Vivo," <u>Twenty-Third Annual Meeting of the American Society for Bone and Mineral Research, Phoenix, Arizona: Presentation Number SU078 (10/14/2001).</u>
	Tinhofer, I. et al., "Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma," <u>BLOOD 95: 610-618 (2000).</u>
	Vanderkerken, K. et al., "Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse," <u>BRIT J CANCER 76: 451-460 (1997).</u>

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.